A new pharmacological composition with a novel mechanism of action intended to eliminate germinated spores and vegetative cells of Clostridium difficile (CD), to treat the recurrence of the infection.
This technology includes a new pharmacological composition with a totally new mechanism of action intended to eliminate germinated spores and vegetative cells of Clostridium difficile (CD), to treat the recurrence of the infection caused by this pathogen. The combination of the generic components of the formulation inhibits both the internalization of CD spores in the intestine of patients and the triggering of spore germination and, therefore, allows the efficient elimination of the germinated spores as well vegetative cells.
The pharmaceutical composition allows the control of at least 50% of the episodes of recurrence associated with the infection, since spores are attacked, unlike the traditional treatments based on antibiotics, which only act at the level of the vegetative cells. Likewise, the potential drug could be manufactured and administered in different modalities, including encapsulated in nanoparticles, allowing it to be delivered to specific areas in the body and also released in a controlled manner. Additionally, it should be noted that all the constituents of the composition are already approved by the FDA, which reduces the risk and cost involved in developing a drug by simplifying toxicology and safety studies.
The technology is currently in TRL-4: Non-GLP in vivo demonstration of activity and efficacy. IP is currently under national phases (US, CA, EP) and a second international patent was submitted to protect the nanoencapsulated form, which increases efficacy.
Current development status
Laboratory prototypes
Applications
Treatment of intrahospital infections
Prevention for ICU patients
Desired business relationship
Patent licensing
Joint ventures
Technology development
Scientific research is one of the fundamental pillars sustaining the solid prestige that the Universidad Andres Bello has established over its 26 years of history. In fact, UNAB was the first non-traditional Chilean university to be accredited in research.
Each one of UNAB’s research centers has hosted investigators who have led important scientific and technological advancements. UNAB promotes research in a wide range of areas, from galaxies, biotechnology, nanoparticles, farming/agriculture, sustainable development, medicine, and new pathologies to social conflicts and education.
Create your free account to connect with Universidad Andres Bello and thousands of other innovative organizations and professionals worldwide
Send a request for information
to Universidad Andres Bello
Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.
Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support
